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Laboratory examination showed normal hematology, elec-
trolytes, and liver function tests. The serum creatinine was
1.4 mg/dL; corrected creatinine clearance, 70 mL/min; protein-
uria, 13.7 g/day; and serum albumin, 1.9 g/dL. All laboratory
screenings for secondary causes were negative or normal in-
cluding complement profile, antinuclear antibody, antineutro-
philic cytoplasmic antibodies, hepatitis B and C serology, HIV
serology, and serum immunoglobulins. A Doppler ultrasound
examination showed normal renal size with patent veins and
no other abnormality. A chest radiograph was normal and
examination of the stools for occult blood was negative 3 3.
Serum cholesterol was 425 mg/dL; LDL, 232 mg/dL; and serum
triglycerides, 180 mg/dL. Renal biopsy revealed 27 glomeruli;
of these, 2 were globally sclerosed and the rest showed diffuse
moderate thickening of the glomerular basement membrane
(GBM) with minimal mesangial matrix increase and focal mild
CASE PRESENTATION patchy interstitial edema and tubular atrophy, but no cellular
proliferation. Immunofluorescence microscopy revealed 31A 49-year-old Portuguese man presented five years ago with
staining for both IgG and C3 in a diffuse granular pattern alonga two-day history of shortness of breath. Over the previous
the GBM. Results were negative for all other immunoglobulins.two to three months, he had noticed increasing swelling of his
Electron microscopy revealed diffuse epithelial cell foot pro-ankles, especially after prolonged standing and, for four to five
cess effacement and numerous, uniformly sized, electron-densedays prior to admission, moderate central abdominal bloating.
deposits along the GBM in a subepithelial location with projec-When directly questioned, he also reported that he had noticed
tions of the GBM between the deposits. There were no mesan-increased frothiness on urination for the previous three months.
gial deposits.He denied paroxysmal nocturnal dyspnea and orthopnea.
The patient initially was treated by his local nephrologistThere was no history of fever, skin rash, or arthralgias. His
with corticosteroids (prednisone, 2 mg/kg) on alternate daysmedical history included mild hypertension for five years, con-
for eight weeks. The proteinuria remained .10 g/day and thetrolled by lisinopril, 10 mg/day. He had a 25 pack-year smoking
patient remained edematous; he developed cushingoid facieshistory. He had no known allergies and no family history of
and gastrointestinal distress. The prednisone was tapered andrenal disease or diabetes. He had been a construction worker
the patient was managed conservatively. After six months ofuntil six months prior to admission, but he had had no exposure
continued angiotensin-converting-enzyme (ACE) inhibitorto chemicals or hydrocarbons. The patient was divorced and
therapy and dietary protein restriction (0.8 g/kg/day), the pa-had no children.
tient remained severely nephrotic and symptomatic. He wasPhysical examination revealed a slightly overweight man referred for a second opinion, and three options were explained
whose blood pressure was 160/85 mm Hg and whose heart rate to him with their inherent risks and benefits: continued conser-
was 76 beats/min and regular. His jugular venous pressure was vative treatment, a six-month course of alternating a cytotoxic
difficult to detect. His chest was clear. Abdominal examination agent with corticosteroids, or cyclosporine. The patient was
revealed shifting dullness; he had severe edema of both legs concerned about additional steroid effects and about infertility,
and the sacrum. Urinalysis showed 41 protein and 31 blood; and he opted for the course of cyclosporine. Cyclosporine was
microscopic analysis disclosed 8 to 10 red blood cells and 3 to begun at 3 mg/kg/day, with the trough level by monoclonal assay
5 granular casts per high-power field. targeted between 150 and 225 ng/mL. The proteinuria gradually
declined and his renal function remained stable. After eight
months, his proteinuria was ,0.2 g/day and his serum creatinineThe Nephrology Forum is funded in part by grants from Amgen,
was 1.2 mg/dL; the corrected creatinine clearance was 90Incorporated; Merck & Co., Incorporated; and Dialysis Clinic, Incorpo-
mL/min. The cyclosporine was discontinued after 10 months.rated.
His cholesterol profile normalized but his hypertension per-
Key words: clinical trials, chronic renal failure, progressive renal fail- sisted. The ACE inhibitor continued to provide good blood
ure, nephrotic syndrome. pressure control, and at his most recent follow-up visit two
months ago, the serum creatinine was 1.2 mg/dL; creatinine
clearance, 88 mL/min; and urine protein excretion, 0.12 g/day.Ó 2001 by the International Society of Nephrology
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DISCUSSION plement by cobra venom serum prevents the subsequent
proteinuria confirm the role of complement in the patho-Dr. Daniel Cattran (Associate Director of Nephrol-
genesis. The podocyte normally retrieves the MAC fromogy, University Health Network, Professor of Medicine,
the immune deposits by endocytosis, transports themUniversity of Toronto, Toronto, Ontario, Canada): Mem-
across the cell, and discharges them by exocytosis intobranous glomerulonephropathy (MGN) remains the
the urinary space [11]. This process might account formost common cause of adult-onset nephrotic syndrome
the appearance of these fragments in the urine of patientsin the world [1]. Its high incidence, despite its overall
with membranous nephropathy [12]. How this sublyticgood prognosis, still makes MGN the second or third
injury from the complex produces proteinuria is unclear.most common primary glomerulonephritis in world reg-
The MAC can activate the formation of radical oxygenistries to progress to end-stage renal disease [2, 3]. Al-
species in the rat model, and treatment with anti-oxidantsthough in the industrialized countries the most common
significantly reduces the proteinuria without preventingvariant is idiopathic MGN, infectious agents such as ma-
formation of the deposit [8]. The MAC also can inducelaria in Africa [4, 5] and hepatitis B in parts of Asia are
production of specific proteinases, such as gelatinase andmore frequent causes [6]. Etiology also varies with age.
metalloproteinase-9, and these proteinases might lead toIn Europe and North America, a variety of malignant
collagen degradation in the glomerular basement mem-tumors have been associated with MGN, with increased
brane (GBM) and subsequently to increased protein per-frequency beyond the fifth decade [7]. This patient’s
meability. The podocyte response to injury is not a prolif-ethnicity, site of residence, age, and the negative screen-
erative one, but rather hypertrophy and increased matrixing tests for secondary causes strongly support an idio-
production. Specific isoforms of transforming growthpathic etiology, and I will focus on that variant of MGN
factor beta and their receptors are up-regulated in thein this Forum.
model, and this up-regulation might mediate accumula-
tion of the excess matrix in experimental and humanPathophysiology
disease [13].
The Heymann model of experimental membranous
The cellular response to complement attack, rather
nephropathy in rats, which closely mimics the human than a proliferative reaction, occurs through alteration
disease, suggests that the highly specialized and termi- in the expression of specific cell-cycle proteins and results
nally differentiated glomerular epithelial cell or podo- in podocyte hypertrophy, excess matrix formation, and
cyte is the target of injury [8]. Research in the experimen- glomerulosclerosis, according to studies by Shankland
tal model has focused on the identification of the et al [14]. Other authors have suggested that the cell’s
responsible antigen(s) and the subsequent immune re- response to injury is due to activation of specific signal
sponse, the role of complement, and the delineation of pathways. Cybulsky et al recently have shown that cyto-
the injury process following the activation of comple- plasmic phospholipase A2 was increased by C5b-9 in
ment [9]. The antigenic targets of the antibody response glomeruli of rats with Heymann nephritis [15]. This in-
in the experimental model have been localized to the crease in turn released more arachidonic acid precursors,
membrane of the glomerular epithelial cell and are spe- which are important in the synthesis of eicosanoids, such
cifically a 515 kD glycoprotein called megalin, a poly- as prostaglandins, thromboxanes, and leukotrienes, all
specific receptor related to the low-density lipoprotein substances that have been implicated in GBM injury.
receptor family, and an associated 44 kD protein, known Interruption of the phospholipase activation could lead
as the receptor-associated protein or RAP [8]. A primary to a new approach to the treatment of the human disease.
role for the T-cell is clear in this model. A CD41 T-cell- The molecular pathogenesis of human membranous ne-
dependent, humoral response results in glomerular im- phropathy, however, remains largely unknown. Despite
munoglobulin deposition and complement activation. the similarities in the pathology and the elegant dissec-
The CD41 help for antibody response is a function of tion of the molecular basis of the injury in the experimen-
the Th2 cell, which produces interleukin (IL) -4, -5, -6, tal model, parallel findings in the human disease remain
-10, and -13. Early in the course of the disease, both elusive. Neither the antigenic equivalent to megalin nor
glomerular and interstitial T-cells as well as macrophage the beneficial effects of the various experimental thera-
infiltrates are found. A role for cell-mediated injury is peutic agents have been duplicated in humans.
supported by the observations that depletion of the cyto- The difficulty in extrapolating information from the
toxic CD81 T-cell reduces the injury and that mono- experimental model to human disease suggests that cer-
clonal anti-CD4 and anti-CD8 treatment modifies the tain variables in the human host are important. The
disease [10]. Complement activation also is important in exploration of genetic factors that influence susceptibil-
producing the glomerular injury. The finding of the ity and/or progression are preliminary, but studies have
C5b–9 membrane attack complex (MAC) within the im- shown a higher-than-expected association with the
HLA-DR2 allele in the Japanese population [16] and themune deposits and the recognition that depletion of com-
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tation versus at end stage. In France the incidence of
idiopathic MGN is between 1.2 and 1.7 per 100,000 popu-
lation, with an age peak between 60 and 79 years. In all
age groups, the gender ratio was almost equal [22]. In
Japan and elsewhere, a similar gender distribution exists
at the start of the process [23, 24]. However, studies
have consistently found that the ratio at end-stage renal
disease has shifted to 2 to 3:1 male:female [2, 3]. These
data indicate that gender strongly influences the severity
of the disease. Moreover, the only two factors associated
with spontaneous remission are persistent low-grade
(subnephrotic) proteinuria and female gender [25]. The
relapse rate from complete remission is also high, varying
between 30% and 50%, but prognosis for these patients
remains excellent, with urinary protein excretion in the
great majority remaining subnephrotic and only 5%
Fig. 1. Probability of renal survival from a pooled analysis of all 32 progressing to chronic renal insufficiency [25, 26]. Over-
studies (reproduced with permission from the National Kidney Founda- all, approximately 30% of patients undergo spontaneoustion) [20].
remission (vide supra); about 30% progress to renal fail-
ure, 30% have variable degrees of proteinuria but stable
function for many years, and about 10% die of nonrenal
literature contains descriptions of a few cases in identical causes [27, 28]. Other factors at presentation that have
twins [17]. A recent study using molecular techniques in been associated with a poor prognosis include male gen-
a cohort of patients with idiopathic MGN from England der, older age, high levels of proteinuria, and abnormal
and Greece extended an earlier HLA serologic associa- renal function; histologic factors include tubular intersti-
tion with DR3 [18]. A particular variation in the gene tial changes and degree of glomerulosclerosis [29–34].
polymorphism of the DR locus, DRB1*0301, was associ- The problem in associating these factors with progno-
ated with the disease. No relationship was apparent sis, however, is their qualitative nature and poor specific-
amongst any of the tested genotypes with severity or ity. An alternate approach based on dynamic changes in
progression of the process, but the numbers of patients renal function does produce a semiquantitative risk of
were small and the observation period limited. The rela- progression [35, 36]. It uses the clinical parameters of
tionship of genetic factors to human idiopathic MGN is proteinuria and creatinine clearance estimates over fixed
still preliminary, but given the variability in its natural periods of time. In its simplest form, this approach dem-
history, it is highly likely that susceptibility factors and onstrated that the overall accuracy of predicting progres-
factors associated with progression will be found. sion to chronic renal failure when proteinuria values over
a 6-month period were persistently greater than 4 g/day
Natural history was 71%, $6 g/day was 79%, and $8 g/day was 84%
The natural history of idiopathic MGN has been docu- (Table 1). If the patient’s renal function was impaired
mented in several studies and must be integrated into any at the beginning of these time frames and/or significantly
management plan. Although a wide variation in outcome deteriorated over the 6 months of observation, accuracy
has been reported, a review of 11 reports of the natural was even higher and sensitivity was substantially greater,
history of the disease demonstrated a 10-year renal sur- as demonstrated by the percentage value under the R
vival within the relatively tight band of 70% to 90% [19]. value in Table 1. The advantages of the algorithm are
A more current pooled analysis of 32 studies estimated its reliance on very few factors, all of which are standard
survival between 65% and 75% at 10 years and 60% at laboratory measurements of renal function, and its dy-
15 years (Fig. 1) [20]. Some of even this small scatter is namic nature, which allows recalculating the risk of pro-
probably the result of variations in diagnostic criteria, gression over the course of the patient’s disease. Age,
choices of end point, baseline characteristics, and statisti- gender, degree of sclerosis on biopsy, and presence of
cal techniques [21]. This relatively good prognosis is hypertension are important factors in univariate analyses
likely an underestimate of today’s outcome, given the but are not independent of the factors in the model and
introduction within the last decade of more potent anti- hence do not add to the predictive value of the algorithm.
hypertensive medications and lowered ideal levels for The effects of idiopathic MGN on nonrenal- and renal-
both systolic and diastolic blood pressure. related morbidity and mortality are more difficult to
Gender seems to influence progression. Support for determine from the literature. Reviews from Finland and
the United States show that a similar high proportionthis can be gleaned by looking at gender ratio at presen-
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Table 1. Test characteristics (%) of predicting chronic renal insufficiency in Canadian patients
Six-month minimum
Proteinuria persistent proteinuria
$3.5 g/day at Full model
time of biopsy 4 g/day 6 g/day 8 g/day (R$0.3)
Sensitivity 93 81 64 58 83
Specificity 38 67 85 93 86
Positive
predictive value 34 46 59 75 67
Negative
predictive value 94 91 87 87 94
Accuracy 52 71 79 84 85
Data from Reference 36.
of deaths, between 30% and 60%, are nonrenal-related The long-term prognosis for low-risk patients is excel-
[25, 28]. Whether their cause is due to comorbid condi- lent. Our validation study examined more than 300 pa-
tions, the effects of the disease, or the treatment is diffi- tients from three distinct geographic regions who were
cult to discern. But details from the reports reveal that followed for more than 5 years. We found that only 5%
most of the deaths are premature (mean age 51) and of patients with these criteria went on to develop chronic
due either to cardiovascular disease or to cancer [37]. renal insufficiency [36]. Blood pressure control and strat-
egies for reduction of urinary protein excretion should be
Treatment implemented through the use of agents such as the angio-
I think it will be useful if we consider therapeutics in tensin-converting-enzyme inhibitors. Immunosuppressive
four categories. The first, specific immunosuppressive drugs are not recommended and, in the majority of cases,
therapy, is aimed at modulating the immune component treatment of the secondary effects of the disease is not
of the disease. The second, nonspecific therapy, focuses necessary. Because a small percentage of patients do
on reducing proteinuria and secondarily slowing disease progress, monitoring of their renal function, proteinuria,
progression. The third comprises treatment of the sec- and blood pressure should be continued and assessment
ondary effects of the disease, and the fourth is treatment of their risk of progression periodically recalculated.
aimed at reducing the complications of the immune- As one would expect, the individuals classified as me-
modulating drugs. dium-risk patients did not fare as well as did the low-
Specific immunosuppressive treatment. The observa- risk patients. The entry criteria for patients in the two
tions on the natural history of idiopathic MGN and our randomized trials that studied the effects of corticoste-
ability to predict outcome should perhaps be the back- roid therapy alone in idiopathic MGN would place these
ground upon which current immunosuppressive proto- patients in the medium risk category [38, 39]. Prednisone
cols are assessed. One approach would be to first estab- alone was ineffective in inducing and sustaining a reduc-
lish risk of progression using the results of our algorithm. tion in proteinuria in these trials. The follow-up periods
We could examine the six-month period around the entry
were less than four years, and the dose and duration
point of the major studies, segregate the patients into
varied, but the evidence does not support the use ofrisk categories, and then discuss the trial results in the
corticosteroids as a single agent in the management ofcontext of prognostic grouping. Although somewhat im-
MGN patients in this risk category. Ponticelli and co-precise given the lack of details provided in the reports,
workers in Italy have found benefit when corticosteroidsthis approach would allow us to assess specific therapies
are combined with a cytotoxic agent. They observed afrom the point of view of risk as well as benefit, the
significant increase both in remissions in proteinuria andoverriding concern both of patients and physicians when
renal survival [40, 41]. Therapy given for six monthsconsidering treatment options.
consisted of 1 g of intravenous methylprednisolone onLet us define the categories for risk of progression.
the first 3 days of months 1, 3, and 5, followed by 27Low-risk patients have normal serum creatinine and cre-
days of oral methylprednisolone (0.5 mg/kg/day) alter-atinine clearance values and a peak proteinuria ,4 g/day
nating in months 2, 4, and 6 with chlorambucil (0.2 mg/kg/over 6 months of observation. Medium-risk patients have
day). After 10 years of follow-up, 8% of treated patientsnormal or nearly normal serum creatinine and creatinine
versus 40% of untreated patients had reached end-stageclearance values and proteinuria $4 g/day but ,8 g/day
renal disease (P 5 0.004). Of the treated group, 43% ofover 6 months of observation. Finally, high-risk patients
the time versus 78% of the placebo group’s time washave either abnormal or deteriorating serum creatinine
spent in a nephrotic state (P 5 0.0001). In a secondand creatinine clearance values and/or persistent pro-
teinuria $8 g/day over 6 months of observation. trial, these authors used the same 6-month routine but
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substituted cyclophosphamide for chlorambucil and to prednisone alone produced no benefit in a recent
randomized trial that documented progressive renal in-found a benefit similar to that in their first trial [42].
However, in this study, approximately 30% of patients sufficiency prior to treatment (mean entry creatinine
level, 2.5 mg/dL) [49]. Long-term oral cyclophosphamidein both groups relapsed within 30 months of stopping
treatment. Both regimens appeared to be quite safe; with or without prednisone has been used in two small,
nonrandomized, case-controlled studies in high-risk pa-only 10% of patients discontinued treatment because of
adverse effects. tients and although both studies showed a benefit, study
design limitations plus the risks of prolonged cytotoxicWe recently completed a six-month randomized trial
comparing cyclosporine with placebo in 51 patients with therapy such as infertility, infection, and malignancy are
significant and have limited this approach [50, 51].idiopathic MGN (abstract; Cattran et al for the North
American Nephrotic Syndrome Study Group, J Am Soc In our randomized controlled trial of patients with
declining function (mean creatinine, 2.2 mg/dL at entry),Nephrol 9:85A, 1999). These patients were in the me-
dium-risk category for progression, as they had 4 to one year of cyclosporine (mean dose, 3.8 mg/kg) signifi-
cantly reduced proteinuria (P 5 0.02) and slowed the8 g/day proteinuria over a six-month observation period
despite control of hypertension and a restricted-protein rate of disease progression (P , 0.02); both of these
results were sustained in more than 50% of patients fordiet of 0.8 g/kg/day. The mean cyclosporine dose was
3.7 6 2.0 mg/kg. Seventy-five percent of the treated group as long as two years [52]. However, the number of pa-
tients was small, and the drug is expensive and nephro-versus 22% of the control group entered a remission (P 5
0.003). This response was maintained for as long as one toxic, so careful patient selection and ongoing monitor-
ing for adverse events must be part of this approach. Anyear after test medication in 48% of the patients receiv-
ing cyclosporine versus only 13% of the patients given earlier uncontrolled study in 15 patients with high-grade
proteinuria resistant to corticosteroid therapy suggesteda placebo (P 5 0.007). Renal insufficiency occurred in
two patients in each group, but the overall rate of renal a similar benefit with cyclosporine, but the relapse rate
was high, approximately 30% [53]. The dose and longfunctional deterioration, defined by the slope of creati-
nine clearance, was flat and the same in both patient duration of cyclosporine therapy is supported by a recent
report from the German collaborative group. In a reviewpopulations over the active treatment and follow-up pe-
riods. Cyclosporine was well tolerated, and no one had of 41 high-risk idiopathic MGN patients treated with
cyclosporine, 14 (34%) achieved a complete remission.to discontinue treatment because of adverse effects.
The percentage of high-risk patients with idiopathic The mean cyclosporine dose was 3.3 mg/kg, and the
time to complete remission averaged 225 days (quartilesMGN is small, and very few trials have selected these
patients for study. In the one randomized trial of cortico- 120–459). The patients were considered to be at high
risk because 70% had been resistant to other immuno-steroids alone in patients with high-grade proteinuria
(mean, 10.6 g/day but normal renal function), predniso- suppressive agents, and their proteinuria averaged 11 g/d
prior to treatment [54].lone conferred no benefit on either the progression rate
or on proteinuria [43]. In a subgroup analysis of patients Nonimmunologic treatment. Dietary protein restric-
tion has never been associated with complete remissionwith initial renal insufficiency in one of the other trials
using corticosteroids alone, no difference was seen in of the nephrotic syndrome in idiopathic MGN. However,
prospective protein-restriction studies and two meta-the rate of deterioration over four years of follow-up
[39]. In a small uncontrolled study of 15 patients with analyses have shown a reduction in both proteinuria and
progression rate as a function of initial urinary proteinidiopathic MGN and a progressive decline in renal func-
tion, treatment comprised pulse methylprednisolone for level [55–58]. Most patients with idiopathic MGN have
heavy proteinuria, so it seems rational for us to modestlyfive days plus an oral prednisone taper [44]. Renal func-
tion initially stabilized in 9 of the patients treated, but restrict their protein intake (0.8 g/kg/day), provided we
continue to monitor the patient’s protein and energyat last follow-up, 2 had died and 5 had gone on to end-
stage renal disease. These results suggest that the benefits intake and nutritional status [59].
Treatment of hypertension also improves proteinuriawere transient. Three groups have used chorambucil in
modified versions of the Italian regimen in high-risk pa- and slows progression of renal failure. In several studies
of diabetic and nondiabetic patients, the ACE inhibitorstients [45–48]. In the total of 34 patients in these studies,
approximately 50% had a sustained improvement in have shown a greater benefit than that accounted for by
their antihypertensive effects alone [57, 60]. This addi-function, but the rate of adverse effects was high, even
with an appropriate dose adjustment of the chlorambucil. tional benefit also has been demonstrated in patients
with idiopathic MGN, but these studies have been smallWhether the therapy was given too late or is less effective
in the most severe cases of idiopathic MGN cannot be and with limited follow-up [61, 62]. The mechanism for
ACE inhibitors’ renoprotective effect is not fully under-answered without a controlled trial in this select popula-
tion. Pulse cyclophosphamide plus prednisone compared stood but in part might be related to their lowering of
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proteinuria and the subsequent reduction in interstitial lems, but this ability has remained elusive even with the
advent of screening for common genetic risk factors forscarring from the decrease in tubular trafficking of pro-
tein moieties [63, 64]. hypercoagulability [76]. Data on complications of oral
anticoagulant therapy in non-nephrotic populations haveTreatment of the secondary effects of the disease. Few
data have been published on the morbidity and mortality recently been better defined. A 14% annual risk of bleed-
ing exists in patients with cardiovascular disease whoassociated with the hyperlipidemia and thromboembo-
lism that occur in patients with persistent high-grade take anticoagulants, but only 2% of these events are
serious or life-threatening, and the fatality rate is #0.5%proteinuria, impaired renal function, or both. However,
the burden of cardiovascular disease seen in end-stage [77]. In a decision analysis, Bellomo and Atkins weighed
the risks of prophylactic anticoagulation versus the cur-renal disease programs is substantial; it is by far the
most common cause of death in both the dialysis and rent approach of waiting for a symptomatic thromboem-
bolic episode. They calculated an overall reduction intransplant populations [65–67]. A variety of abnormali-
ties in the lipid profile have been reported with the ne- morbid events of 32% with prophylactic anticoagulation
[74], but they admit that their analysis was flawed byphrotic syndrome, but the most frequent pattern has
been an increase in total cholesterol with normal or low the lack of information in the literature about the point
estimates necessary for calculating event rates and thelevels of high density lipoprotein (HDL) and increased
low density lipoprotein (LDL). It is likely that the dyslipi- inability to balance the morbidity associated with a hem-
orrhagic versus a thrombotic complication. The majoritydemia plays a central role in the increased cardiovascular
risk and perhaps the thromboembolic disease in these of nephrologists today use oral anticoagulant therapy as
primary prevention only in high-risk patients or not atpatients [68, 69]. The lipid metabolism regulators of the
hydroxy methylglutaryl co-enzyme A reductase class all, and they reserve its general use until after occurrence
of an event. The correctness of this approach remains(HMG-CoA) have been effective in the management
of hyperlipidemia in patients with persistent nephrotic- controversial; further study is required.
Prophylaxis. Bone loss is related to both the dosagerange proteinuria [70]. Although no randomized trials
have been done or are likely to be carried out in this and duration of corticosteroid therapy and is greatest in
the first three to six months of treatment. Well-designedspecific group, many nephrologists have applied this in-
formation and the safety and efficacy studies from other trials in patients exposed to long-term corticosteroid
therapy have shown that etidronate therapy preventspopulations to justify use of these drugs in patients with
idiopathic MGN [71]. both lumbar and trochanteric bone loss [78]. A 1997
study reported a 40% reduction in new vertebral frac-Studies have shown variation in the risk of thrombo-
embolic disease in idiopathic MGN. Some studies have tures in women, especially in the postmenopausal group,
and very little in the way of adverse effects of the medica-reported an incidence of renal vein thrombosis and
thromboembolic phenomena as high as 50% in patients tion. Etidronate administration should be considered in
the patient with idiopathic MGN when prolonged courseswith severe membranous nephropathy; other investiga-
tors have quoted an incidence as low as 20% [72]. Part of corticosteroid therapy are utilized, provided there is on-
going monitoring in patients at risk for renal stones and/orof this wide range is probably related to the rigor of the
screening process and to the detection methods em- renal insufficiency. Similarly, trimethoprim-sulfameth-
oxazole (TMP-SMX) significantly reduces the incidenceployed. The most recent report, published in 1993, found
deep venous thrombosis in 11%, pulmonary emboli in of Pneumocystis carinii pneumonia in patients undergo-
ing prolonged immunosuppressive therapy both for solidanother 11%, and renal vein thrombosis in 35% of their
patients with idiopathic MGN [73]. The death rate from organ transplants and certain autoimmune disorders
[79]. Use of TMP-SMX is recommended when patientsthromboembolism in their total group was 14% but was
42% in high-risk patients over a follow-up of only 4.5 with idiopathic MGN are exposed to such therapy.
years; these data emphasize the magnitude of this issue
Conclusions[74]. In vitro and in vivo studies have provided evidence
of multiple factors that promote a hypercoagulable state Management of the patient with MGN has changed
over the past two decades. An algorithm that summarizesin patients with the nephrotic syndrome [75]. These
range from platelet abnormalities to hyperfibrinogene- many of the treatment approaches is outlined in Figure 2.
The following general rules are also suggested:mia. The highest risk of thromboembolism occurs in pa-
tients whose albumin levels are below 2.5 g/L, but this (1) Establish whether MGN is primary (idiopathic) or
secondary. If the latter, identify the inciting agent andapparently easy screening test for identifying which pa-
tients to treat with anticoagulation is countered by the take appropriate actions for its removal or treatment.
(2) In the majority of patients who have normal renalconcern that patients with hypoalbuminemia have a
greater propensity to bleed. It would be ideal if we could function at presentation, renal function should be moni-
tored over a six-month period while the patient is receiv-predict those who will experience thromboembolic prob-
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Fig. 2. Guideline for the treatment of idiopathic membranous nephropathy. Patients can change from one category to another during the course
of follow-up. Abbreviation is: ACEI, angiotensin-converting-enzyme inhibiting drug. *Supported by evidence from a controlled trial. **Introduction
of risk reduction strategies for both secondary effects of disease and adverse effects of immunotherapy.
ing conservative therapy. A risk of progression score one of the best indicators of prognosis. It may be that
the control population had a higher and more persistentshould be established. If during this observation period
level of proteinuria compared with the treatment grouphigh-grade proteinuria persists and/or renal function de-
and that this increase eventually produced the poor out-teriorates, treatment for the secondary effects of the
come. This difference could have been missed in thedisease such as a lipid-lowering agent and possibly an
analysis, as only qualitative proteinuria was reported,anticoagulant should be introduced.
not actual proteinuria levels over time. The magnitude(3) In patients with medium risk of progression, the
of the decline in renal function in the control patientsbest evidence-based medicine supports the monthly cy-
would still be unusual, however, that is, a 10% annualcling routine of cyclophosphamide or chlorambucil alter-
decline in GFR and 25% of patients doubling their initialnating with prednisone for six months.
serum creatinine level in only 15 months. This finding is(4) In patients with high risk of progression, cyclo-
not in keeping with other reports of the natural historysporine for 6 to 12 months, or the cyclophosphamide or
of the disease. Remember that even the best randomizedchlorambucil/prednisone regimen with appropriate drug
controlled study has a chance of imbalance at the timedose adjustments should be implemented.
of randomization.
Dr. Harrington: An earlier observational study in
QUESTIONS AND ANSWERS Boston involved only nephrotic patients, including those
Dr. John T. Harrington (Dean, Tufts University with membranous GN. There was a clear difference in
School of Medicine, Boston, Massachusetts): In the study the response rate of those who were treated within six
chaired by Coggins [38], the criticism has been that there months of diagnosis of their disease compared with those
was “something wrong” with the control group. I was a treated after six months [80]. No one in the latter group
participant in the direction of that study. Since we could had a response. Did you look at that aspect of treatment?
not identify anything different in our control group as Dr. Cattran: This question raises several issues. I’ll
compared with other membranous control groups at time restrict my comments to membranous GN. The first issue
zero, might you have an explanation? is, how accurate are we at estimating when the disease
Dr. Cattran: I do not have the answer, but it might be started? Clinically, I think not very good. I would guess
worthwhile to look specifically at the levels of proteinuria this extends over weeks to months as the patient pro-
ceeds through a series of physicians before seeing aand their persistence in light of what we now know is
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nephrologist. Then the patient has to have a renal biopsy Dr. Ramad Prasad (Nephrology Fellow, Toronto Gen-
eral Division of the University Health Network, Toronto):and histologic confirmation. Even this process assumes
that following disease onset, symptomatic edema quickly Is there a role for mycophenolate mofetil (MMF) in the
treatment of idiopathic membranous nephropathy?occurs. All these are known to be quite variable. If not
by clinical features alone, can we tell the duration of the Dr. Cattran: In studies looking at the effect of MMF
on the Heymann model of membranous GN, the drugdisease from the biopsy? In most studies the relationship
between the staging of the disease by electron micros- interfered with both the cell- and humoral-mediated
components, although it had no effect if started after thecopy, the time of onset of the process, and the start of
treatment is lacking. Since we cannot precisely estimate disease was established. The results in human membra-
nous GN are mostly sporadic. Dr. Appel’s group recentlyonset by symptoms or pathology, it is unlikely that we
can determine from either our study or the literature reported a 50% reduction in proteinuria in 6 of 16 pa-
tients (40%) after 6 months of MMF treatment [81].whether the timing of the treatment is crucial. Further
complicating the relationship between onset, stage, and Almost all these patients had been resistant to other
drug therapies. The jury is still out, but I think a con-treatment response is the natural history of membranous
GN. As many as 30% of patients will have a spontaneous trolled trial is worth considering. It may be that treatment
of membranous nephropathy will become more like can-remission, often in the first year or two, and few have
biopsies post remission to indicate what has happened cer chemotherapy, that is, after selection of the high-
risk group, pulse treatment will be followed by a combi-at the glomerular level. This spontaneous remission rate
will confound the interpretation of any therapeutic study nation of agents but in lower doses than our current
single-drug approach and perhaps for a longer duration.that starts early, especially if there is no control popula-
tion. Based on this, I think that the increased accuracy An indication of the need for a new approach is sug-
gested by the literature that reports a relapse rate ofgained in assessing prognosis by using an observation
period might outweigh the theoretical advantages of 30% to 40% within 2 years of discontinuing the medica-
tion not only with cyclosporine treatment, but also withearly treatment.
Dr. Gerry Arbus (Pediatric Nephrologist, The Hospi- chlorambucil-prednisone and with cyclophosphamide-
prednisone [42].tal for Sick Children, Toronto): We don’t see a lot of
idiopathic membranous GN in children. Is your patient Dr. Sanjeev Gulati (Nephrology Fellow, The Hospi-
tal for Sick Children): Is the natural history of idiopathiccured because he’s now clear of protein, or does he have
a chance of relapsing? If he does progress to dialysis or membranous nephropathy in children any different from
that in adults? How would you recommend managingtransplantation, what are his chances of having a recur-
rence of the membranous disease? the child with this disorder?
Dr. Cattran: Idiopathic membranous GN is rare inDr. Cattran: About 30% of membranous GN cases
will relapse subsequent to a complete remission. The great children. As far as I’m aware, there are no published
natural history studies in children and none on specificmajority who do, however, will have stable long-term renal
function and will relapse only to subnephrotic-range pro- treatment in this age group. If you do see such a child,
be careful to rule out secondary causes. Certainly lupusteinuria. In our recent report of 82 patients in complete
remission, only 9 developed mild renal insufficiency 5 to nephritis, including the membranous variant, can occur in
this age group and can precede the development of sys-25 years after disease onset, and none progressed to
ESRD. Dr. Ponticelli reported the only other large group temic symptoms and/or laboratory findings of this disease.
Dr. Marc Goldstein (Staff Nephrologist, St. Michael’sfollowed after a complete remission and found a similar
relapse rate and stable long-term function [25, 26]. So Hospital, Toronto): I’d like to return to the question of
early treatment. I agree with you that if you’re going torelapses do occur in a significant percentage of patients,
but the relapses tend to be moderate in regard to protein- treat with a potentially dangerous therapy, it is important
to identify patients who are at risk of progression. In theuria and rarely progress to renal insufficiency.
Our patient stopped cyclosporine treatment 4 years ago. group we treated with long-term oral cyclophosphamide,
we treated late and still had a high response rate. TheseAlthough he is less likely to relapse as time goes on, we
have seen it occur as long as 12 years after a complete patients already had renal functional impairment, and
their disease had been present for several years. I’m notremission. The recurrence of membranous nephropathy
after transplantation is in the range of 5% to 10%, and convinced that early treatment is justifiable because of
the risks of therapy.I’m not aware of any factors that predict recurrence.
Patients who do develop end-stage renal disease obvi- Dr. Cattran: I agree this is an important question
and should perhaps be addressed in a formal study.ously have the worse variant of the disease, and it would
not be unexpected that susceptibility to recurrence re- Dr. Judith Miller (Staff Nephrologist, Toronto Gen-
eral Division of the University Health Network): Couldsides within the genetic make-up of the host. Currently
this is pure speculation. you expand on the impact of gender on the progression
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rate in membranous nephropathy and the mechanisms of thromboembolic events approaching 50% and a death
rate that was much higher in this group [74]. Thereforethat might be involved?
Dr. Cattran: A better prognosis in females has been we should carefully monitor for such episodes and, if
detected, treat them with long-term anticoagulants.suggested in most of the primary glomerular diseases for
many years, but we still haven’t figured out the precise Whether all patients with membranous GN should be
treated prophylactically is more controversial, but mostmechanism. Your own work indicates that there are gen-
der differences both in normal renal hemodynamics and practicing nephrologists don’t initiate anticoagulant ther-
apy until after the first event.in the kidney’s response to blockade of the renin-angio-
tensin system [82]. Other experimental work supports an Dr. Harrington: In our observational study many
years ago, almost no one whose 24-hour urine proteininteraction between the renin-angiotensin system and
intraglomerular pressure that is at least partially estrogen excretion was less than 2 g progressed to renal failure
[80]. Have you looked at your ,4 g group to see whatdependent [83]. Also, evidence from animal data sug-
gests that transforming growth factor beta significantly happened to those with 0 to 2 g/day?
Dr. Cattran: No, we have not looked specifically atinfluences glomerular matrix production, and matrix pro-
duction in turn might be modified by the presence of this level of proteinuria, but my guess would be exactly
what you suggest. It would certainly fit with the currentestrogen [84]. Thus, gender and progression might be
linked through both the hemodynamic and the cell re- data which indicate that the level of proteinuria is an
important predictive factor. There are also accumulatingsponse systems. How this occurs in women and whether
it is limited to their fertile period remains to be deter- data that above a certain grade, the proteinuria per se
is nephrotoxic to the tubulointerstitial compartment. Inmined. A further gender difference is suggested by a
recent summary of familial cases of membranous GN. our algorithm, both the proteinuria level and its persis-
tence are used to semiquantitate the likelihood of pro-The 25 cases reported included only one female [85]. In
another recent case report supporting the importance of gression. The algorithm can be used by the physician to
better assess the risks of treatment versus the benefits.gender, two siblings developed membranous GN, but
the male went on to renal failure and the female had a You can often delay or even avoid immunosuppressive
drugs in many patients who are at low risk of progressioncomplete remission [17]. Once we determine the mecha-
nism of the gender effect, perhaps we will be able to by its application.
Dr. Harrington: Can you tell us a bit more aboutintervene by modifying the hormonal factor(s). A whole
new avenue of therapeutics could potentially be opened. megalin? What is it and what does it do? Should I worry
about it?Dr. Murli Krishnan (Nephrology Fellow, Toronto
General Division of the University Health Network): Do Dr. Cattran: Megalin is a normal component of the
podocyte identified in the Heymann model of experi-any histologic findings predict a poor prognosis, and can
we use them to guide therapy? mental membranous GN. It is related to the low-density
lipoprotein family and functions as a multiligand recep-Dr. Cattran: Yes. They include the degree of intersti-
tial fibrosis, glomerular sclerosis, and the severity of the tor for the uptake of a variety of macromolecules. A
second protein, known as RAP (receptor-associated pro-vascular changes. However, in most multivariate analy-
ses, these findings are not independent risk factors. In tein), is closely related to megalin and is an additional
target antigen in the model. Kerjaschki and others havemost studies on prediction, the serum creatinine and
the severity of the proteinuria over time dominate the worked out the relationship between megalin and the
receptor-protein molecule and found that the formationalgorithm. So although histology is associated with prog-
nosis, it does not add anything to the risk profile provid- of the complex between these antigens and their antibod-
ies initiates the disease process but does not proceeding you have the laboratory data. In the final analysis,
it doesn’t matter whether you’re male or female or how to structural changes and proteinuria until complement
binding occurs [8]. Currently, the human equivalent ofthe biopsy looks, it’s the degree of proteinuria, how long
it’s been at that level, and the serum creatinine value this sequence is limited to finding the C5b-9 complex or
MAC in the urine of patients with membranous nephrop-that count.
Dr. Sanjay Maitra (Nephrology Fellow, Toronto Gen- athy. The experimental model mimics human disease in
regard to the pathology, but the identification of theeral Division of the University Health Network): The
high-risk patients have a significant incidence of throm- equivalent of megalin or RAP has not been determined.
In summary, you don’t have to worry about it.boembolism. Do you recommend regular monitoring for
these episodes in these patients? Dr. York Pei: (Staff Nephrologist, Toronto General
Division of the University Health Network): IdiopathicDr. Cattran: We probably should be more vigilant,
especially in patients who have persistent high-grade membranous glomerulonephritis is probably a heteroge-
nous collection of different diseases similar to what hasproteinuria and/or severe hypoalbuminemia. A recent
retrospective review from Australia found a prevalence been found in type 1 and type 2 diabetes. One of the key
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approaches to studying the human problem is to examine their renal reserve is less and might suggest that starting
treatment earlier would preserve more renal function,the familial form of the disease, as seen in the recent
progress in other related glomerular disorders like focal but it also means that their risk of complications from
therapy are likely to be higher. Perhaps we should useglomerulosclerosis. Do you know of any such study in
idiopathic membranous GN? Do such families exist? the same care in selecting patients at risk of progression
as younger patients, and remember that if therapy is toDr. Cattran: The families exist, and some have been
reported, as I mentioned previously [85]. As far as I’m be used, we must make the appropriate dose adjustment
given the patient’s age and impaired clearance.aware, however, there’s no collaborative network cur-
rently in place specifically looking at the familial form
Reprint requests to Dr. Daniel Cattran, Toronto General Division of
of the disease. University Health Network, 101 College Street, CCRW 3-884, Toronto,
Ontario M5G 1l7, Canada.Dr. Goldstein: Is it correct that relapses are much
E-mail: daniel.cattran@uhn.on.camore common after a complete remission from therapy
than after a spontaneous remission, and do we under-
REFERENCESstand what a relapse means at the glomerular level?
Dr. Cattran: The answer to the first question depends 1. Haas M: Changing etiologies of unexplained adult nephrotic syn-
drome: A comparison of renal biopsy findings from 1976-1979 andon which study you review. In the randomized trials
1995-1997. Am J Kidney Dis 30:621–631, 1997
using corticosteroids, there is a trend toward a higher 2. US Renal Data System: USRDS 1999 Annual Data Report. The
National Institutes of Health, National Institute of Diabetes andrelapse rate in the treated group in all three studies [38,
Digestive and Kidney Disease, Bethesda, 199939, 43], but the numbers are small and follow-up is quite
3. Maisonneuve P, Agodoa L, Gellert R, et al: Distribution of
short. In the long-term chlorambucil-prednisone trial primary renal diseases leading to end-stage renal failure in the
United States, Europe and Australia/New Zealand: Results fromfrom Italy, there is also only a trend but in the opposite
an international comparative study. Am J Kidney Dis 35:157–165,direction, that is, the relapse rate was 11 of 24 (46%) in
2000
the treated group and 4 of 7 (57%) in the control group 4. Rabenantoandro R, Rakotondrajao R, Rakotondranaivo S,
Rasamindrakotroka AJ: Renal glomerular lesions and Plasmo-[40]. The relapse rate is an important issue, but at least
dium falciparum infection. Am J Kidney Dis 10:52–55, 1987in the natural history studies, most relapses are associ-
5. Goldman M, Lambert PH: Glomerulopathies associated with par-
ated with a lower grade of proteinuria and rarely associ- asitoses. Nephrologie 6:49–51, 1985
6. Kar NL, Lai FM, Chan KW, et al: The clinical pathological featuresated with deteriorating function. The sequence of events
of hepatitis B virus associated glomerulonephritis. Q J Med 63:323–at the glomerular level is not clear. Histologic studies
333, 1987
focusing on relapse patients are rare. In most cases re- 7. Burstein DM, Korbet SM, Schwartz MM: Membranous glomer-
ulonephritis and malignancy. Am J Kidney Dis 22:5–10, 1993ported, new stage 1 deposits on electron microscopy
8. Kerjaschki D, Neale TJ: Molecular mechanisms of glomerularhave been found. Presumably a fresh wave of whatever
injury in rat experimental membranous nephropathy (Heymann
prompted the original immune complexes has recurred. nephritis). Am J Kidney Dis 7:2518–2525, 1996
In some cases, however, the lesions look like they’ve 9. Shankland SJ: New insights into pathogenesis of membranous
nephropathy. Kidney Int 57:1204–1205, 2000persisted despite the complete clinical and laboratory
10. Penny MJ, Boyd RA, Hall BM: Mycophenolate mofetil preventsremission. To¨rnoth, Honkanen, and Pettersson have sug- the induction of active Heymann nephritis: Association with Th2
gested that the large deposits that extend deeply into cytokine inhibition. J Am Soc Nephrol 9:2272–2282, 1998
11. Couser WG, Schultz M, Pruchno CJ: Role of C5b-9 in experi-the GBM but whose surface is still exposed to the subepi-
mental membranous nephropathy. Nephrol Dial Transplant 1:25–thelial space represent this type of clinical pattern [86]. 31, 1992
This would allow for ongoing activation of complement 12. Kon SP, Coupes B, Short CD, et al: Urinary C5b-9 excretion
and clinical course in idiopathic human membranous nephropathy.and the subsequent chemokine release essential for the
Kidney Int 48:1953–1958, 1995damage indicated by the return of proteinuria. It may 13. Shankland SJ, Pippin J, Pichler RH, et al: Differential expression
be that both scenarios exist in the human condition. It of transforming growth factor-b isoforms and receptors in experi-
mental membranous nephropathy. Kidney Int 50:116–124, 1996is highly unlikely that a single factor is going to explain
14. Shankland SJ, Floege J, Thomas SE, et al: Cyclin kinase inhibitorsall the membranous GN variants, but the cases that do are increased during experimental membranous nephropathy: Po-
remit and relapse, as well as the familial ones, should tential role in limiting glomerular epithelial cell proliferation in
vivo. Kidney Int 52:404–413, 1997be good targets for studying potential genetic influences.
15. Cybulsky AV, Takano T, Papillon J, McTavish AJ: Comple-Dr. Gulati: Should older patients with membranous
ment-induced phospholipase A2 activation in experimental mem-
GN be considered for treatment earlier because they are branous nephropathy. Kidney Int 57:1052–1062, 2000
16. Hiki Y, Kobayashi Y, Itoh I, Kashiwagi N: Strong association ofat a higher risk of progression?
HLA-DR2 and MT1 with idiopathic membranous nephropathy inDr. Cattran: I don’t think so. We have demonstrated
Japan. Kidney Int 25:953–967, 1984
that the rate of deterioration in the elderly is the same 17. Guella A, Akhtar M, Ronco P: Idiopathic membranous nephrop-
athy in identical twins. Am J Kidney Dis 29:115–118, 1997as in the younger patient [87]. Baseline serum creatinine
18. Vaughan RW, Tighe MR, Boki K, et al: An analysis of HLA classalso did not differ, but correcting creatinine clearances
II gene polymorphism in British and Greek idiopathic membranous
for age and muscle mass significantly lowered the initial nephropathy patients. Eur J Immunogenet 22:179–186, 1995
19. Cattran DC, Pei Y, Greenwood C: Predicting progression in mem-value for GFR in the older population. This means that
Nephrology Forum: Idiopathic membranous GN 1993
branous glomerulonephritis. Nephrol Dial Transplant 7(Suppl 1): 44. Short CD, Solomon LR, Gokal R, Mallick NP: Methylpredniso-
48–52, 1992 lone in patients with membranous nephropathy and declining renal
20. Hogan SL, Muller KE, Jennette JC, Falk RJ: A review of function. Q J Med 65:929–940, 1987
therapeutic studies of idiopathic membranous glomerulopathy. Am 45. Mathieson PW, Turner AN, Maidment CG, et al: Prednisolone
J Kidney Dis 25:862–875, 1995 and chlorambucil treatment in idiopathic membranous nephropa-
21. Marx BE, Marx M: Prognosis of idiopathic membranous nephrop- thy with deteriorating renal function. Lancet 2:869–872, 1988
athy: A methodologic meta-analysis. Kidney Int 51:873–879, 1997 46. Warwick GL, Geddes CG, Boulton-Jones JM: Prednisolone and
22. Simon P, Ramee MP, Autuly V, et al: Epidemiology of primary chlorambucil therapy for idiopathic membranous nephropathy
glomerular diseases in a French region: Variations according to with progressive renal failure. Q J Med 87:223–229, 1994
period and age. Kidney Int 46:1192–1198, 1994 47. Wetzels JFM, Hoitsma AJ, Koene RAP: Immunosuppression for
23. Abe S, Amagasaki SY, Kato E, et al: Idiopathic membranous membranous nephropathy. (letter) Lancet 1:211, 1989
glomerulonephritis: Aspects of geographical differences. J Clin 48. Stirling CM, Simpson K, Boulton-Jones JM: Immunosuppression
Pathol 39:1193–1198, 1986 and outcome in idiopathic membranous nephropathy. Q J Med
24. Harrison DJ, Thomson D, Macdonald MK: Membranous glo- 91:159–164, 1998
merulonephritis. J Clin Pathol 39:167–171, 1986 49. Falk RJ, Hogan SL, Muller KE, Jennette JC, et al: Treatment
25. Laluck BJ Jr, Cattran DC: Prognosis after a complete remission of progressive membranous glomerulopathy: A randomized trial
in adult patients with idiopathic membranous nephropathy. Am comparing cyclophosphamide and corticosteroids with corticoste-
J Kidney Dis 33:1026–1032, 1999 roids alone. Ann Intern Med 116:438–445, 1992
26. Ponticelli C, Passerini P, Altieri P, et al: Remissions and relapses 50. Jindal K, West M, Bear R, Goldstein M: Long-term benefits of
in idiopathic membranous nephropathy. Nephrol Dial Transplant therapy with cyclophosphamide and prednisone in patients with
7(Suppl 1):85–90, 1992 membranous glomerulonephritis and impaired renal function. Am
27. Honkanen E, Tornroth T, Gronhagen-Riska C: Natural history, J Kidney Dis 19:61–67, 1992
clinical course and morphological evolution of membranous ne- 51. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission
phropathy. Nephrol Dial Transplant 7(Suppl 1):35–41, 1992 of membranous glomerulonephritis after cyclophosphamide and
28. Donadio JV Jr, Torres VE, Velosa JA, et al: Idiopathic membra- prednisone. Ann Intern Med 114:725–730, 1991
nous nephropathy: The natural history of untreated patients. Kid- 52. Cattran DC, Greenwood C, Ritchie S, et al: A controlled trial
ney Int 33:708–715, 1988 of cyclosporine in patients with progressive membranous nephrop-
29. Tu WH, Petitti DB, Biava CG, et al: Membranous nephropathy: athy. Kidney Int 47:1130–1135, 1995
Predictors of terminal renal failure. Nephron 36:118–124, 1984 53. Rostoker G, Belghiti D, Maadi AB, et al: Long-term cyclosporine
30. Davison AM, Cameron JS, Kerr DN, et al: The natural history A therapy for severe idiopathic membranous nephropathy. Neph-
of renal function in untreated idiopathic membranous glomerulo- ron 63:335–341, 1993
nephritis in adults. Clin Nephrol 22:61–67, 1984 54. Fritsche L, Budde K, Farber L, et al: Treatment of membranous
31. Zucchelli P, Ponticelli C, Cagnoli L, Passerini P: Long-term glomerulopathy with cyclosporine A: How much patience is re-
outcome of idiopathic membranous nephropathy with nephrotic quired? Nephrol Dial Transplant 14:1036–1037, 1999syndrome. Nephrol Dial Transplant 2:73–78, 1987 55. Amico GD, Gentile MG, Fellin G, et al: Effect of dietary protein32. Murphy BF, Fairley KF, Kincaid-Smith PS: Idiopathic membra-
restriction on the progression of renal failure: A prospective ran-nous glomerulonephritis: Long-term follow-up in 139 cases. Clin
domized trial. Nephrol Dial Transplant 9:1590–1594, 1994Nephrol 30:175–181, 1988
56. Gansevoort RT, de Zeeuw D, de Jong PR: Additive antiprotein-33. Schieppati A, Mosconi L, Perna A, et al: Prognosis of untreated
uric effect of ACE inhibition and low-protein diet in human renalpatients with idiopathic membranous nephropathy. N Engl J Med
disease. Nephrol Dial Transplant 10:497–504, 1995329:85–89, 1993
57. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control,34. Magil AB: Tubulointerstitial lesions in human membranous glo-
proteinuria, and the progression of renal disease. Ann Intern Medmerulonephritis: Relationship to proteinuria. Am J Kidney Dis
123:754–762, 199525:375–379, 1995
58. Pedrini MT, Levey AS, Lau J, et al: The effect of dietary protein35. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insuffi-
restriction on the progression of diabetic and nondiabetic renalciency in idiopathic membranous glomerulonephritis. Kidney Int
disease: A meta-analysis. Ann Intern Med 124:627–632, 199642:960–966, 1992
59. Kopple JD, Levey AS, Greene T, et al: Effect of dietary protein36. Cattran DC, Pei Y, Greenwood CM, et al: Validation of a pre-
restriction on nutritional status in the Modification of Diet in Renaldictive model of idiopathic membranous nephropathy: Its clinical
Disease study. Kidney Int 52:778–791, 1997and research implications. Kidney Int 51:901–907, 1997
60. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al: Antiprotein-37. Honkanen E: Survival in idiopathic membranous glomerulone-
uric effect of blood-pressure-lowering agents: A meta-analysis ofphritis. Clin Nephrol 25:122–128, 1986
comparative trials. Nephrol Dial Transplant 10:1963–1974, 199538. A controlled study of short-term prednisone treatment in adults
61. Thomas DM, Hillis AN, Coles GA, et al: Enalapril can treat thewith membranous nephropathy: Collaborative Study of the Adult
proteinuria of membranous glomerulonephritis without detrimentIdiopathic Nephrotic Syndrome. N Engl J Med 301:1301–1306,
to systemic or renal hemodynamics. Am J Kidney Dis 18:38–43,1979
199139. Cattran DC, Delmore T, Roscoe J, et al: A randomized controlled
62. Rostoker G, Ben Maadi A, Remy P, et al: Low-dose angiotensin-trial of prednisone in patients with idiopathic membranous ne-
converting-enzyme inhibitor captopril to reduce proteinuria inphropathy. N Engl J Med 320:210–215, 1989
adult idiopathic membranous nephropathy: A prospective study40. Ponticelli C, Zucchelli P, Imbasciati E, et al: Controlled trial of
of long-term treatment. Nephrol Dial Transplant 10:25–29, 1995methylprednisolone and chlorambucil in idiopathic membranous
63. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective prop-nephropathy. N Engl J Med 310:946–950, 1984
erties of ACE-inhibition in non-diabetic nephropathies with non-41. Ponticelli C, Zucchelli P, Passerini P, et al: A 10-year follow-
nephrotic proteinuria. Lancet 354:359–364, 1999up of a randomized study with methylprednisolone and chlorambu-
64. Abbate M, Benigni A, Bertani T, Remuzzi G: Nephrotoxicitycil in membranous nephropathy. Kidney Int 48:1600–1604, 1995
of increased glomerular protein traffic. Nephrol Dial Transplant42. Ponticelli C, Altieri P, Scolari F, et al: A randomized study
14:304–312, 1999comparing methylprednisolone plus chlorambucil versus methyl-
65. Ojo AO, Hanson JA, Wolfe RA, et al: Long-term survival inprednisolone plus cyclophosphamide in idiopathic membranous
renal transplant recipients with renal grafts. Kidney Int 57:307–313,nephropathy. J Am Soc Nephrol 9:444–450, 1998
200043. Cameron JS, Healy MJ, Adu D, et al: The Medical Research
66. US Renal Data Systems: USRDS 1995 Annual Data Report. TheCouncil trial of short-term high-dose alternate day prednisolone
National Institutes of Health National Institute of Diabetes andin idiopathic membranous nephropathy with nephrotic syndrome
in adults. Q J Med 74:133–156, 1990 Digestive and Kidney Diseases, Bethesda, 1995
Nephrology Forum: Idiopathic membranous GN1994
67. ANZDATA Registry Report 1999. Australia and New Zealand heart disease: Results in actual cardiology practice. Can J Cardiol
16:153–161, 2000Dialysis and Transplant Registry. Adelaide, South Australia
78. Adachi J, Bensen WG, Brown J, et al: Intermittent etidronate68. Wheeler DC, Bernard DB: Lipid abnormalities in the nephrotic
therapy to prevent corticosteroid induced osteoporosis. N Englsyndrome: Causes, consequences, and treatment. Am J Kidney Dis
J Med 337:382–387, 199723:331–346, 1994
79. Ognibene FP, Shelhamer JH, Hoffman GS, et al: Pneumocystis69. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The in-
carinii pneumonia: A major complication of immunosuppressivecreased risk of coronary heart disease associated with nephrotic
therapy in patients with Wegener’s granulomatosis. Am J Respsyndrome. Kidney Int 44:638–642, 1993
Crit Care Med 151:795–799, 199570. Spitalewitz S, Porush JG, Cattran DC, Wright N: Treatment
80. Miller RB, Harrington JT, Ramos CP, et al: Long-term resultsof hyperlipidemia in the nephrotic syndrome: The effects of pravas-
of steroid therapy in adults with idiopathic nephrotic syndrome.tatin therapy. Am J Kidney Dis 22:143–150, 1993
Am J Med 46:919–929, 196971. Scandinavian Simvastatin Survival Study: Randomized trial of
81. Miller G, Zimmerman R III, Radhakrishan J, Appel G: Use ofcholesterol lowering in 4444 patients with coronary heart disease.
mycophenolate mofetil in resistant membranous nephropathy. AmLancet 344:1383–1389, 1994
J Kidney Dis 36:250–256, 200072. Wagoner RD, Stanson AW, Holley KE, Winter CS: Renal vein
82. Miller JA, Anacta LA, Cattran DC: Impact of gender on thethrombosis in idiopathic membranous glomerulopathy and ne-
renal response to angiotensin II. Kidney Int 55:278–285, 1999phrotic syndrome: Incidence and significance. Kidney Int 23:368–
83. Evans JK, Naish PF, Aber GM: Oestrogen-induced changes in374, 1983
renal haemodynamics in the rat: influence of plasma and intrarenal73. Bellomo R, Wood C, Wagner I, et al: Idiopathic membranous
renin. Clin Sci 71:613–619, 1986nephropathy in an Australian population: The incidence of throm- 84. Silbiger S, Lei J, Ziyadeh FN, Neugarten J: Estradiol reverses
boembolism and its impact on the natural history. (letter) Nephron TGF-beta 1-stimulated type IV collagen gene transcription in mu-
63:240–241, 1993 rine mesangial cells. Am J Physiol 274:F1113–F1118, 1998
74. Bellomo R, Atkins RC: Membranous nephropathy and thrombo- 85. Maccario M, Segagni S, Efficace E, et al: Idiopathic membranous
embolism: Is prophylactic anticoagulation warranted? (editorial) nephropathy in two siblings. Nephron Dial Transplant 10:108–110,
Nephron 63:249–254, 1993 1995
75. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ: Thrombosis 86. To¨rnroth T, Honkanen E, Pettersson E: The evolution of mem-
and hemostasis in renal disease. Kidney Int 46:287–296, 1994 branous glomerulonephritis reconsidered: New insights from a
76. Fabri D, Belangero VM, Annichino-Bizzacchi JM, Arruda VR: study on relapsing disease. Clin Nephrol 28:107–117, 1987
Inherited risk factors for thrombophilia in children with nephrotic 87. Zent R, Nagai R, Cattran DC: Idiopathic membranous nephropa-
syndrome. Eur J Pediatr 157:939–942, 1998 thy in the elderly: A comparative study. Am J Kidney Dis 29:200–
206, 199777. Baggio D, Madore F, Lalonde G: Oral anticoagulant therapy for
